Navigation Links
Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley
Date:4/4/2013

NORCROSS, Ga., April 4, 2013 /PRNewswire/ -- Gilbert Amelio , former CEO of Apple, and Rod Martin , former counsel to PayPal, both on the Board of Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in today's Atlanta Journal Constitution discussing the future of Atlanta as the emerging Silicon Valley for changing the world by curing the big diseases, and why they moved Galectin Therapeutics to Atlanta.

"The world needs a biotech Silicon Valley. We believe that Atlanta is perfectly poised to become just that," wrote Amelio and Martin.

To read the full op-ed from the Atlanta Journal-Constitution, click here. To schedule interviews with Gil Amelio and Rod Martin , please contact Cheri Jacobus at cherijacobus@aol.com, or (202) 257-4638.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.


'/>"/>
SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
3. Turning smartphones into secure and versatile keys
4. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
5. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
6. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
7. A Homegrown Smile? Atlanta Dentist Examines New Research on the Biological Teeth Replacement
8. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
9. Avocado Oil: The Olive Oil Of The Americas?
10. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
11. Researching graphene nanoelectronics for a post-silicon world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):